Fluvoxamine reduces COVID-19 risk: real-time meta analysis of 21 studies
, Dec 2025
30th treatment shown to reduce risk in
November 2021, now with p = 0.00014 from 21 studies, recognized in 2 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Significantly lower risk is seen for mortality, hospitalization, progression, recovery, and cases. 14 studies from 14 independent teams in 8 countries show significant benefit.
Meta analysis using the most serious outcome reported shows 39% [21‑52%] lower risk. Results are similar for Randomized Controlled Trials.
Results are very robust — in exclusion sensitivity analysis 12 of 21 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
Control Fluvoxamine
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.
9 other meta analyses show significant improvements with fluvoxamine for mortality1-3, hospitalization1,4-8, progression2,8, and severity9.
9 meta analyses show significant improvements with fluvoxamine for mortality1-3,
hospitalization1,4-8 ,
progression2,8, and
severity9.
1.
Deng et al., Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: A systematic review and meta-analysis, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2023.01.010.
2.
Prasanth et al., A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications, Scientific Reports, doi:10.1038/s41598-024-64260-9.
3.
Fico et al., Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis, European Neuropsychopharmacology, doi:10.1016/j.euroneuro.2022.10.004.
4.
Lee et al., Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis, JAMA Network Open, doi:10.1001/jamanetworkopen.2022.6269.
5.
Lu et al., Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.10.010.
6.
Marcec et al., A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference, Journal of Infection, doi:10.1016/j.jinf.2022.11.011.
7.
Deng (B) et al., Evaluating fluvoxamine for the outpatient treatment of COVID‐19: A systematic review and meta‐analysis, Reviews in Medical Virology, doi:10.1002/rmv.2501.
Covid Analysis et al., Dec 2025, preprint, 1 author.